M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity Pharmaceutical TechnologyThrough this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).NeuroscienceRead full story pharminent August 4, 2026 (Last updated: August 8, 2026) Pharmaceutical Technology Through this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs). Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pathos AI signs two cancer deals with Alphamab and AZNext: Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline Clearout Related Stories M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026 M&A / Deals Pathos AI signs two cancer deals with Alphamab and AZ pharminent August 4, 2026 M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026
